Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is a monoclonal antibody that targets amyloid beta A4 protein and acts by selectively binding and eliminating amyloid beta plaques, thought to be clinically significant for the treatment of Alzheimer’s disease.
Let's personalize your content